NUVO PHARMS INC
SpecialtyNUVO PHARMS INC is a specialty pharmaceutical company focused on Immunology, Gastroenterology.
NUVO PHARMS INC's Key Drugs
NUVO PHARMS INC's core commercial portfolio centers on CHLORDIAZEPOXIDE HYDROCHLORIDE AND CLIDINIUM BROMIDE, spanning Immunology and Gastroenterology — its most strategically important drugs approved in the last 15 years.
NUVO PHARMS INC's Recent FDA Approvals
New NDA/BLA approvals for NUVO PHARMS INC over the last two years — novel drugs only, excluding generics and label supplements.
NUVO PHARMS INC's Therapeutic Areas
NUVO PHARMS INC's approved drugs and pipeline span 2 therapeutic areas, led by Immunology and Gastroenterology, across 0 biologic and 2 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
NUVO PHARMS INC's Top Competitors
NUVO PHARMS INC's closest competitors by therapeutic-area and drug-target overlap include Johnson & Johnson, Bristol-Myers Squibb, and BAUSCH. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
NUVO PHARMS INC Pipeline Snapshot
Active clinical trials for NUVO PHARMS INC across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • CHLORDIAZEPOXIDE HYDROCHLORIDE AND CLIDINIUM BROMIDE leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Immunology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Discontinued (0)
Company Info
- First Approval
- 1998-12-24
- Latest
- 2023-03-08
- Applications
- 12